EUVIMEDEUVIMED entdecken
Open Access

Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic response to the cytotoxic threat

Hellen Röttgen, Lana Theurer, Teresa Peccerella, Ketaki Sandu, Johanna Weiss, Jürgen Burhenne, John P Neoptolemos, Beate Köberle, Dirk Theile

Oncology Reports · 2025

DOI: 10.3892/or.2025.9027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Reports, 2025. Verfasst von Hellen Röttgen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine IX‑Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg Univ…. Hauptthemen laut MEDLINE: Oxaliplatin, Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxaliplatinDrug Resistance, NeoplasmCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAntineoplastic AgentsHumansApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticOrganoidsMaleFemale

Stichwörter der Autor:innen

AsPC‑1BxPC‑3drug uptakehuman patient‑derived organoidsoxaliplatin resistancepancreatic ductal adenocarcinoma

Substanzen

OxaliplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Internal Medicine IX‑Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg University Hospital, D‑69120 Heidelberg, Germany.
  • Department of Food Chemistry and Toxicology, Karlsruhe Institute of Technology, D‑76131 Karlsruhe, Germany.
  • Department of General, Visceral, and Transplantation Surgery, Heidelberg University, Medical Faculty Heidelberg, Heidelberg University Hospital, D‑69120 Heidelberg, Germany.

Zitieren

APA

Röttgen, H., Theurer, L., Peccerella, T., Sandu, K., Weiss, J., Burhenne, J., Neoptolemos, J. P., Köberle, B., & Theile, D. (2025). Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic response to the cytotoxic threat. Oncology Reports. https://doi.org/10.3892/or.2025.9027

Vancouver

Röttgen H, Theurer L, Peccerella T, Sandu K, Weiss J, Burhenne J, et al. Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic response to the cytotoxic threat. Oncology Reports. 2025. doi:10.3892/or.2025.9027

BibTeX
@article{Rttgen2025,
  author = {Röttgen, Hellen and Theurer, Lana and Peccerella, Teresa and Sandu, Ketaki and Weiss, Johanna and Burhenne, Jürgen and Neoptolemos, John P and Köberle, Beate and Theile, Dirk},
  title = {Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic response to the cytotoxic threat},
  journal = {Oncology Reports},
  year = {2025},
  doi = {10.3892/or.2025.9027}
}
Kostenlos starten →